All In Biotech

Drug Trial Radar · NCT05622526

Evaluate the Efficacy, Safety and Tolerability of Fecal Microbiota Transfer for the Treatment of Patients With Nonalcoholic Steatohepatitis

Randomized, Double-blind, Multicenter Study to Evaluate the Efficacy, Safety and Tolerability of Fecal Microbiota Transfer by Capsules vs. Placebo for the Treatment of Patients With Nonalcoholic Steatohepatitis

Last checked: Nov 19, 2026Latest source record: Nov 1, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

96

Planned (sponsor's estimate)

Start

Jan 1, 2024

Primary completion

Nov 1, 2025

Study completion Mar 1, 2026

Sponsor

Lead sponsor
Instituto de Investigación Marqués de ValdecillaAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Nov 18, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The EMOTION study is a multicentric, double-blind, controlled, parallel-group, phase IIa randomized Clinical trial to evaluate the efficacy, safety and tolerability of TMF capsules for the treatment of patients with NASH. The clinical trial has two stages: * Screening phase with a duration of 12 weeks to classify patients based on lifestyle modifications. * Treatment phase where patients will be randomized and stratified 2:1 to treatment: * Experimental for n=64 patients. * Placebo control for n=32 patients.

Conditions

  • Patients With Nonalcoholic Steatohepatitis

Interventions

  • Group 1 or Experimental groupDrug

    Capsules of fecal microbiota transplantation

  • Group 2 or Control groupOther

    capsules of placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of patients with improvement of fat fraction by proton density by MRI and no worsening of activity or fibrosis.Time frame: 72 weeks
  2. number of adverse events (AEs), serious AEs, AEs resulting in discontinuation of study treatment, AEs of special interest, and changes in vital signs and laboratory valuesTime frame: 72 weeks

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.